RATIONALE FOR USE OF ALFACALCIDOL IN COMBINATION WITH BISPHOSPHONATES IN POSTMENOPAUSAL AND SENILE FORMS OF SYSTEMIC OSTEOPOROSIS


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Assessment of the dynamics of bone mineral density (BMD) and parameters of calcium homeostasis in 163 patients with postmenopausal and senile forms of systemic osteoporosis treated with alfacalcidol in combination with bisphosphonates (112 patients received zoledronic acid, 51 - ibandronic acid) and calcium carbonate (1000-1200 mg/day), for 1 year confirmed that alfacalcidol, being a synthetic analogue of D-hormone, has a positive impact at personalized doses on most of the processes, which are negatively changed using bisphosphonates. In particular, the preservation of normal parameters of calcium homeostasis is a guarantee of BMD increase in this case.

全文:

受限制的访问

作者简介

S. Rodionova

Email: rod06@inbox.ru
MD, Prof., Head of Scientific and Clinical Center of Osteoporosis FSBI «Central Scientific Research Institute of Traumatology and Orthopedics n.a. N.N. Priorov» of RMH Moscow

U. Khakimov

Clinical Research Center of Osteoporosis FSBI CITO n.a. N.N. Priorov of RMH Moscow

参考

  1. Lin J.H. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996; 18:75-85.
  2. Follet H., Li J., Phipps R.J., Hui S., Condon K., Burr D.B. Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading. Bone. 2007;40(4):1172-77.
  3. Cranney A., Wells G., Yetisir E., Adami S., Cooper C., Delmas P.D., Miller P.D., Papapoulos S., Reginster J.Y., Sambrook P.N., Silverman S., Siris E., Adachi J.D. Ibandronate for the prevention of nonvertebral fractures a pooled analysis of individual patient data. Osteoporos. Int. 2009;20:291-97.
  4. Rogers M.J. New insights into the molecular mechanismsof action of bisphosphonates. Curr. Pharm. Des. 2003;9:2643-58.
  5. Kohno N., Aogi K., Minami H., Nakamura S., Asaga T., Iino Y., Watanabe T., Goessl C., Ohashi Y., Takashima S. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J. Clin. Oncol. 2005;23(15):3314-21.
  6. Sorscher S.M. Electrolyte abnormalities with zoledronic acid therapy, Cancer J. 2002;8(4):348; author reply 348-49.
  7. DeLuca H.F., Schnoes H.K. Vitamin D: recent advances. Annu. Rev. Biochem. 1983; 52:411-39.
  8. Nordin B.E., Morris H.A. Osteoporosis and vitamin D. J. Cell Biochem. 1992;49(1):19-25.
  9. Schacht E., Dukas L., Richy F. Combined therapies in osteoporosis: Bisphosphonates and Vitamin D-hormone analogs. J. Musculoskelet. Neuronal interact. 2007;7(2):174-84.
  10. Shiraishi A., Higashi S., Ohkawa H., Kubodera N., Hirasawa T., Ezawa I., ikeda K., Ogata E. The advantage of alfacalcidol over vitamin D in the treatment of osteoporosis. Calcif. Tissue int. 1999;65:311-16.
  11. Nuti R., Bianchi G., Brandi M.L. Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis. Rheumatology. 2006; 26(5):445-53.
  12. Richy F., Schacht E., Bruyere O. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: A comparative meta-analysis. Calcif. Tissue int. 2005;76:176-86.
  13. Avenell A., Gillespie W.J., Gillespie L.D., O'Connell D.L. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst. Rev. 2005;3:CD000227.
  14. Eastell R., Riggs B.L. Vitamin D and osteoporosis. in: Feldman D., Glorieux F.H., Pike J.W. (eds.). Vitamin D. Academic Press, New York. 1997. Р 695-711.
  15. Гланц С. Медико-биологическая статистика. 1999. 438 с.
  16. Boonen S., Reginter J.Y., Kaufman J.M., Lippuner K., Zanchetta J., Langdah B., Rizzoli R., Lipschitz S., Dimai B., Witvrouw R., Eriksen E., Brixen K., Russo L., Claessens F., Papanastasiou P., Antunez O., Su G., Bucci-Rechtweg C., Hruska J., incera E., Vanderschueren D., Orwoll E. Fracture risk and zoledronic acid therapy in men with osteoporosis. N. Engl. J. Med. 2012;367: 1714-23.
  17. Gnant M., Mlineritsch B., Luschin-Ebengreuth G., Kainberger F., Kässmann H., Piswanger-Sölkner J.C., Seifert M., Ploner F., Menzel C., Dubsky P., Fitzal F., Bjelic-Radisic V., Steger G., Greil R., Marth C., Kubista E., Samonigg H., Wohlmuth P., Mittlböck M., Jakesz R.; Austrian Breast and Colorectal Cancer Study Group (ABCSG). Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 2008;9(9):840-49.
  18. Родионова С.С., Буклемишев Ю.В. Эффективность золендроновой кислоты у пациентов с системным остеопорозом и проблема не ответчиков на лечения. Вестник травматологии. 2015;4:39-43.
  19. Lips P., Duong T., Oleksik A., Black D., Cummings S., Cox D., Nickelsen T. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J. Clin. Endocrinol. Metab. 2001;86(3):1212-21.
  20. Fleisch H. The bisphosphonate ibandronate, given daily as well as discontinuously, decreases bone resorption and increases calcium retention as assessed by 45Ca kinetics in the intact rat. Osteoporos. Int. 1996;6:166-70.
  21. Durchschlag E., Paschalis E.P., Zoehrer R., Roschger P., Fratzl P., Recker R., Phipps R., Klaushofer K. Bone material propertiesin trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate. J. Bone Miner. Res. 2006;21:1581-90.
  22. Boskey A.L., Spevak L., Weinstein R.S. Spectroscopic markers of bone quality in alendronate treated postmenopausal women. Osteoporos. Int. 2009;20:793-800.
  23. Mashiba T. Is SSBT associated with atypical femoral fracture? SSBT is associated with atypical femoral fracture - pathophysiology of atypical femoral fractures. Clin. Calcium. 2012;22(6):914-18.
  24. Kwek E.B., Lenart B.A., Neviaser A.S., Lyman S., Chang C.C., Edobor-Osula F., Steele B., van der Meulen M.C., Lorich D.G., Lane J.M. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study Osteoporos. Int. 2009;20(8):1353-62.
  25. Neviaser A.S., Lane J.M., Lenart B.A., Edobor-Osula F., Lorich D.G. Low-energy femoral shaft fractures associated with alendronate use. J. Orthop. Trauma. 2008;22(5):346-50.
  26. Panda D.K., Miao D., Bolivar I., Li J., Huo R., Hendy G.N., Goltzman D. Inactivation of the 25-hydroxyvitamin D lalpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J. Biol. Chem.2004;279(16): 1675-76.
  27. Lau K.H.W., Baylink D.J. Treatment of 1,25(OH)2D3(Dhormone) deficiency/resistance with D-hormone and analogs. Osteologie. 2001;10:28-39.
  28. Morrison N.A., George P.M., Vaughan T., Tilyard M.W., Frampton C.M., Gilchrist N.L. Vitamin D receptor genotypes influence the success of calcitriol therapy for recurrent vertebral fracture in osteoporosis. Pharmacogenet. Genomics. 2005;15(2):127-35.
  29. Родионова С.С., Еловой-Вронский А.А., Бернакевич А.И. Альфакальцидол или колекальциферол в комбинации с ибандроновой кислотой при лечении постменопаузального системного остеопороза. Остеопороз и остеопатии. 2014;1:25-8.
  30. Mehl B., Delling G., Schlindwein I. Do markers of bone metabolism reflect the presence of a high- or low-turnover state of bone metabolism? Med. Klin. (Munich). 2002;97(10):588-94.
  31. Ones K., Schacht E., Dukas L., Caglar N. Effects of Combined Treatment with Alendronate and Alfacalcidol on Bone Mineral Density and Bone Turnover in Postmenopausal Osteoporosis: A two-years, randomized, multiarm, controlled trial. Internet J. Epidemiol. 2006;4(1).
  32. Dusso A., Broun J., Slatopolsky E. Vitamin D. Am. J. Physiol. Renal Physiol. 2005;289(1):8-28.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2016
##common.cookie##